CGTX
COGNITION THERAPEUTICS INC
NASDAQ · Healthcare · Biotechnology · US
$0.73
−0.33%Oct 13, 2026, 10:00 UTC
COGNITION THERAPEUTICS INC announced the issuance of a composition-of-matter patent extending protection for zervimesine (CT1812) through 2045.
Source:Sep 29, 2026, 11:30 UTC
Cognition Therapeutics scheduled a Type C meeting with the FDA's Division of Neurology for October 20 to align on endpoints for a Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies.
Source:Aug 7, 2026, 00:13 UTC
Cognition Therapeutics, Inc. reported a second-quarter loss of $0.04 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and the year-ago loss of $0.11 per share.
Source:Jun 24, 2026, 11:49 UTC
Cognition Therapeutics received written feedback from the FDA agreeing that psychosis associated with dementia with Lewy bodies could be an approvable outcome and aligning on key aspects of a pivotal trial for Zervimesine (CT1812).
Source: